Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Tue, 30.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry [ … ]
Mon, 15.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, May 15, 2023. The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, and the Chief Operating Officer of the Medical segment, Dr. Lutz Helmke, will resign from the [ … ]
Mon, 15.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, May 15, 2023. The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, and the Chief Operating Officer of the Medical segment, Dr. Lutz Helmke, will resign from the [ … ]
Thu, 11.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 11 May 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was thus 29% lower than in the same quarter of the previous year, mainly due to currency losses as well as [ … ]
Thu, 11.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 11 May 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was thus 29% lower than in the same quarter of the previous year, mainly due to currency losses as well as [ … ]
Mon, 08.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 May 2023 – Following clinical investigations of hypertension specialists in the Netherlands, France, the United States, and China, the Monash Medical Center (Monash Health) and Hudson Institute in Melbourne, Australia, has commenced an investigator initiated clinical study with PentixaPharm’s novel lead compound [68Ga]Ga-PentixaFor target [ … ]
Mon, 08.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 May 2023 – Following clinical investigations of hypertension specialists in the Netherlands, France, the United States, and China, the Monash Medical Center (Monash Health) and Hudson Institute in Melbourne, Australia, has commenced an investigator initiated clinical study with PentixaPharm’s novel lead compound [68Ga]Ga-PentixaFor target [ … ]
Tue, 25.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, April 25, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) will achieve sales of around 58 million EUR (previous year: 50) and a net profit of around 4.7 million EUR (previous year: 6.6) for the first quarter of 2023.
The significant increase in sales results from the renewed growth in demand [ … ]
Tue, 25.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, April 25, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) will achieve sales of around 58 million EUR (previous year: 50) and a net profit of around 4.7 million EUR (previous year: 6.6) for the first quarter of 2023.
The significant increase in sales results from the renewed growth in demand [ … ]
Thu, 20.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority. The approval is the basis for the marketing author [ … ]